CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
STRATIFIX +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03285555
NCT03285555N/ACompleted

Prospective Randomized Trial of Stratafix vs. Vicryl on Operating Room Time and Wound Closure Time in Total Hip Arthroplasty.

The Cleveland Clinic·interventional·Posted Sep 18, 2017·Updated Nov 17, 2020

In Brief

A clinical study evaluating STRATIFIX and VICRYL for Wound; Hip. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The STRATAFIX (Ethicon, Johnson and Johnson, Somerville, New Jersey) Knotless Tissue Control suture device is a barbed suture that uses anchor technology to securely engage with the soft tissues while also eliminating the need for knots. The anchors, or barbs, are pressed out of the device core or formed within the core in a geometric pattern and arranged in a tapered manner to allow the device to pass through tissue in the direction toward the needle during closure. These knotless tissue control devices are deployed using a continuous technique, which is anticipated to be faster and more cost-effective than interrupted suturing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWound; Hip
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 18, 2017
Enrollment StartSep 26, 2017
Primary CompletionJun 30, 2019
Study CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.8 years ago

Interventions

STRATIFIXdevice

STRATIFIX symmetric PDS Plus; Stratifix knotless suture

VICRYLdevice

Vicryl #1